Skip to main content
Erschienen in: European Radiology 5/2021

29.10.2020 | Gastrointestinal

Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma

verfasst von: Atanas Pachev, Lucas Raynaud, Luisa Paulatto, Marco Dioguardi Burgio, Vincent Roche, Carmela Garcia Alba, Annie Sibert, Matthieu Lagadec, Juliette Kavafyan-Lasserre, Catherine Paugam-Burtz, Valérie Vilgrain, Maxime Ronot

Erschienen in: European Radiology | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To prospectively assess the frequency of severe abdominal pain during and after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using the visual analog scale (VAS), and to identify predictive factors.

Methods

Ninety-eight TACE performed in 80 patients (mean 65 ± 12 years old, 60 men) were consecutively and prospectively included. Abdominal pain was considered severe if the VAS ≥ 30/100 after treatment administration, or if opioid analgesic (grades 2–3) intake was required during hospitalization. Patient and tumor characteristics as well as technical factors associated with severe pain were identified by binary logistic regression.

Results

The criterion for severe pain was met in 41/98 (42%) of procedures (peri-procedural pain 30/98 [31%] and opioid consumption during hospitalization 24/98 [25%]). Multivariate analysis identified age (odds ratio [OR] = 0.943 (95% confidence interval 0.895–0.994), p = 0.029), cirrhosis (OR = 0.284 (0.083–0.971), p = 0.045), and alcoholic liver disease (OR = 0.081 (0.010–0.659), p = 0.019) as negative predictive factors of severe abdominal pain. Severe abdominal pain occurred in or after 1/13 (8%), 8/34 (24%), 22/41 (54%), and 10/10 (100%) TACE sessions when none, one, two, and three of the protective factors were absent, respectively (p < 0.001). The area under the ROC curve of the combination of factors for the prediction of severe abdominal pain was 0.779 (CI 0.687–0.871).

Conclusion

Severe abdominal pain was frequent during and after TACE revealing a clinically relevant and underestimated problem. A predictive model based on three readily available clinical variables suggests that young patients without alcoholic liver disease or cirrhosis could benefit from reinforced analgesia.

Key Points

• Severe abdominal pain occurs in 43% of TACE for HCC.
• Younger age, absence of cirrhosis, and absence of alcoholic liver disease were identified as independent predictive factors of severe abdominal pain.
• A simple combination of the three abovementioned features helped predict the occurrence of severe abdominal pain.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391:1301–1314CrossRef Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391:1301–1314CrossRef
2.
Zurück zum Zitat European Association for the Study of the Liver (2018) EASL Clinical Practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236 European Association for the Study of the Liver (2018) EASL Clinical Practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
3.
Zurück zum Zitat Otto G, Herber S, Heise M et al (2006) Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12:1260–1267CrossRef Otto G, Herber S, Heise M et al (2006) Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12:1260–1267CrossRef
4.
Zurück zum Zitat Ravaioli M, Grazi GL, Piscaglia F et al (2008) Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 8:2547–2557CrossRef Ravaioli M, Grazi GL, Piscaglia F et al (2008) Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 8:2547–2557CrossRef
5.
Zurück zum Zitat Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRef Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739CrossRef
6.
Zurück zum Zitat Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRef Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRef
7.
Zurück zum Zitat Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442CrossRef Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442CrossRef
9.
Zurück zum Zitat Pomoni M, Malagari K, Moschouris H et al (2012) Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepatogastroenterology 59:820–825PubMed Pomoni M, Malagari K, Moschouris H et al (2012) Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepatogastroenterology 59:820–825PubMed
10.
Zurück zum Zitat Bouvier A, Ozenne V, Aube C et al (2011) Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 21:1719–1726CrossRef Bouvier A, Ozenne V, Aube C et al (2011) Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 21:1719–1726CrossRef
11.
Zurück zum Zitat Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264CrossRef Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111:255–264CrossRef
12.
Zurück zum Zitat Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC (2001) Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 12:321–326 Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC (2001) Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 12:321–326
13.
Zurück zum Zitat Benzakoun J, Ronot M, Lagadec M et al (2017) Risks factors for severe pain after selective liver transarterial chemoembolization. Liver Int 37:583–591CrossRef Benzakoun J, Ronot M, Lagadec M et al (2017) Risks factors for severe pain after selective liver transarterial chemoembolization. Liver Int 37:583–591CrossRef
14.
Zurück zum Zitat Lang EV, Benotsch EG, Fick LJ et al (2000) Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. Lancet 355:1486–1490CrossRef Lang EV, Benotsch EG, Fick LJ et al (2000) Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. Lancet 355:1486–1490CrossRef
15.
Zurück zum Zitat European Association for the Study of the Liver (2018) EASL Clinical Practice guidelines: management of alcohol-related liver disease. J Hepatol 69:154–181 European Association for the Study of the Liver (2018) EASL Clinical Practice guidelines: management of alcohol-related liver disease. J Hepatol 69:154–181
16.
Zurück zum Zitat Yang H, Seon J, Sung PS et al (2017) Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma: a randomized, double-blinded, placebo-controlled study. J Vasc Interv Radiol 28:1503–1511 e1502CrossRef Yang H, Seon J, Sung PS et al (2017) Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma: a randomized, double-blinded, placebo-controlled study. J Vasc Interv Radiol 28:1503–1511 e1502CrossRef
17.
Zurück zum Zitat Guo JG, Zhao LP, Rao YF et al (2018) Novel multimodal analgesia regimen improves post-TACE pain in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 17:510–516CrossRef Guo JG, Zhao LP, Rao YF et al (2018) Novel multimodal analgesia regimen improves post-TACE pain in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 17:510–516CrossRef
18.
Zurück zum Zitat Jensen KJ, Alpini G, Glaser S (2013) Hepatic nervous system and neurobiology of the liver. Compr Physiol 3:655–665CrossRef Jensen KJ, Alpini G, Glaser S (2013) Hepatic nervous system and neurobiology of the liver. Compr Physiol 3:655–665CrossRef
19.
Zurück zum Zitat Novak DJ, Victor M (1974) The vagus and sympathetic nerves in alcoholic polyneuropathy. Arch Neurol 30:273–284CrossRef Novak DJ, Victor M (1974) The vagus and sympathetic nerves in alcoholic polyneuropathy. Arch Neurol 30:273–284CrossRef
20.
Zurück zum Zitat Lammer J, Malagari K, Vogl T et al (2009) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52CrossRef Lammer J, Malagari K, Vogl T et al (2009) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52CrossRef
22.
Zurück zum Zitat Wang TC, Zhang ZS, Xiao YD (2020) Determination of risk factors for pain after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Pain Res 13:649–656CrossRef Wang TC, Zhang ZS, Xiao YD (2020) Determination of risk factors for pain after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Pain Res 13:649–656CrossRef
23.
Zurück zum Zitat Hatsiopoulou O, Cohen RI, Lang EV (2003) Postprocedure pain management of interventional radiology patients. J Vasc Interv Radiol 14:1373–1385CrossRef Hatsiopoulou O, Cohen RI, Lang EV (2003) Postprocedure pain management of interventional radiology patients. J Vasc Interv Radiol 14:1373–1385CrossRef
24.
Zurück zum Zitat Schupp CJ, Berbaum K, Berbaum M et al (2005) Pain and anxiety during interventional radiologic procedures: effect of patients’ state anxiety at baseline and modulation by nonpharmacologic analgesia adjuncts. J Vasc Interv Radiol 16:1585–1592CrossRef Schupp CJ, Berbaum K, Berbaum M et al (2005) Pain and anxiety during interventional radiologic procedures: effect of patients’ state anxiety at baseline and modulation by nonpharmacologic analgesia adjuncts. J Vasc Interv Radiol 16:1585–1592CrossRef
Metadaten
Titel
Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma
verfasst von
Atanas Pachev
Lucas Raynaud
Luisa Paulatto
Marco Dioguardi Burgio
Vincent Roche
Carmela Garcia Alba
Annie Sibert
Matthieu Lagadec
Juliette Kavafyan-Lasserre
Catherine Paugam-Burtz
Valérie Vilgrain
Maxime Ronot
Publikationsdatum
29.10.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 5/2021
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-020-07404-5

Weitere Artikel der Ausgabe 5/2021

European Radiology 5/2021 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.